skip nav
National Prevention Information Network
Search Help
Other Searches: Search Organizations | Search Materials | Search Campaign Resources | Search Funding
español
Share Share this page on Twitter Share this page on Facebook Share this page on LinkedIn View more options to share this page E-mail this page to a colleague Print this page


<< Back

News

Anti-HIV Antibodies May Spur AIDS Vaccine Development

Abstract
According to Barton Haynes, director of the Duke University Human Vaccine Institute at Duke University School of Medicine, Duke researchers may have discovered how to stimulate production of “broadly neutralizing” antibodies, which could lead to the development of an HIV vaccine. The ability of an African patient to continue producing broadly neutralizing antibodies, even after the virus has mutated, is the basis for the breakthrough. Approximately 20 percent of people infected with HIV generate antibodies that are able to neutralize HIV effectively in its initial and mutated forms. Haynes explained that the first round of broadly neutralizing antibodies appears approximately 14 weeks after the initial HIV infection. This first generation of antibodies binds to a part of the virus that does not change as easily or rapidly, so the antibodies are a potential target for vaccine research. Duke researchers collected blood samples from 400 HIV patients for three years from the time of infection, and mapped the sequential mutations of the virus that stimulated subsequent, weaker generations of antibodies. With this map of antibody development over three years, the research team believes it is possible to stimulate the immune system to produce more of the first generation of broadly neutralizing antibodies, instead of the “subsequent iterations” the immune system produces in response to HIV mutations. Because each person generates “unique versions” of broadly neutralizing antibodies that differ in effectiveness, Haynes believes it will be necessary to map individual pathways to broadly neutralizing antibodies and find commonalities that can be used in a vaccine. The full report, “Co-evolution of a Broadly Neutralizing HIV-1 Antibody and Founder Virus,” was published online in the journal Nature (2013; doi: 10.1038/nature12053).
Source
http://www.time.com/time/
Date of Publication
04/04/2013
Author
Alice Park
Article Type
General media
Article Category
Medical News

Disclaimer: NPIN provides this information as a public service only. The views and information provided about the materials, funding opportunities, and organizations do not necessarily state or reflect those of the U.S. Department of Health and Human Services, CDC, or NPIN.

cdcnpin.org News Record #61375

<< Back

CDCNPIN.org

Contact Us
About Us
HIV Content Notice
Privacy Policy
Policies & Disclaimers
Site Index
Help Using the CDC NPIN Web Site

CDC NPIN Searches

Search Organizations
Search Materials
Search Funding Opportunities
Search Campaign Resources
Help Using the CDC NPIN Searches

CDC NPIN Resources

hivtest.cdc.gov
m.hivtest.cdc.gov
findtbresources.org
STD Awareness Microsite
findstdtest.org
AIDS Gov Logo and Link CDC Logo and Link